Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $13.63
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given a consensus rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in […]
More Stories
MAN GRP PLC/ADR (OTCMKTS:MNGPY) Stock Price Crosses Above 200-Day Moving Average of $1.79
MAN GRP PLC/ADR (OTCMKTS:MNGPY – Get Free Report) passed above its 200-day moving average during trading on Wednesday . The...
SPS Commerce (NASDAQ:SPSC) Issues FY 2024 Earnings Guidance
SPS Commerce (NASDAQ:SPSC – Get Free Report) updated its FY 2024 earnings guidance on Thursday. The company provided earnings per...
ProShares Ultra Bloomberg Crude Oil (NYSEARCA:UCO) Share Price Cross Above Two Hundred Day Moving Average of $31.23
ProShares Ultra Bloomberg Crude Oil (NYSEARCA:UCO – Get Free Report)’s stock price crossed above its two hundred day moving average...
CI Financial (TSE:CIX) Stock Price Crosses Above 200-Day Moving Average of $15.82
CI Financial Corp. (TSE:CIX – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Wednesday...
Toronto Dominion Bank Raises Position in Brown & Brown, Inc. (NYSE:BRO)
Toronto Dominion Bank grew its holdings in Brown & Brown, Inc. (NYSE:BRO – Free Report) by 1.6% in the 1st...
Toronto Dominion Bank Trims Stock Holdings in AvalonBay Communities, Inc. (NYSE:AVB)
Toronto Dominion Bank lowered its stake in shares of AvalonBay Communities, Inc. (NYSE:AVB – Free Report) by 12.5% during the...